Mood Disorders

Bumetanide May Benefit Children With Autism Spectrum Disorder

By December 07, 2018

Behavioral features such as social communication, interactions, and restricted interest were most improved with bumetanide treatment; however, the authors reported no dose-effect relationship in the dose-ranging trial.

Infections Linked to Increased Later Risk for Mental Disorders

December 06, 2018

Subsequent risk increased with infections requiring hospitalization, treatment with anti-infective agents

Life Expectancy in the US Decreased From 2016 to 2017

November 29, 2018

The researchers found that in 2017, life expectancy declined to 78.6 years for the US population.

In-Person vs Facebook Social Contact: Differences in Psychiatric Symptoms

November 29, 2018

There was a correlation between more frequent in-person social contact and a significantly decreased risk for symptoms of major depression and posttraumatic stress disorder relative to contact every few weeks or less.

Report Examines Number of US Children With Autism Diagnosis

November 27, 2018

The researchers found that parents of an estimated 1.5 million US children aged 3 to 17 years (2.5%) reported their child had received a diagnosis and currently had ASD.

Parents of children with autism report greater difficulty accessing health care

November 26, 2018

Parents of children with ASD reported higher demands for health care (i.e. were more likely to have seen a medical provider in the past year and have a personal doctor or nurse), but greater difficulty accessing services.

Transcendental Meditation Benefits Veterans With PTSD

November 19, 2018

Participants were randomly assigned to a TM group (68 participants), prolonged exposure therapy (PE) group (68 participants), or an active control group of PTSD health education (HE; 67 participants).

Increased Risk of Depression, Suicide in Atopic Dermatitis

November 18, 2018

The prevalence of depression in patients with atopic dermatitis was higher than in those without atopic dermatitis.

AMA to Collect Data on Suicide Among Doctors-in-Training

November 15, 2018

"While we have been working hard to reduce burnout and increase access to mental health services for physicians and medical students, it is imperative that we also work toward fully understanding the problem," said AMA Board Member, Ryan Ribeira MD.

Concussion or mild traumatic brain injury linked with increased risk of suicide

November 14, 2018

In this large systematic review and meta-analysis, the risk of suicide was 2 times higher for patients with history of at least 1 concussion or mild TBI.

Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation

By November 13, 2018

NRX-101 combines D-cycloserine (DCS), an N-methyl-D-aspartate (NMDA) receptor antagonist, and lurasidone, a D2/5-HT2a receptor antagonist.

Buprenorphine/Samidorphan Helpful in Refractory Depression

November 06, 2018

In pooled analyses of the 2 studies, consistently greater reduction was seen in MADRS scores from baseline for BUP/SAM 2mg/2mg versus placebo at multiple time points, including EOT and average change from baseline to week three through EOT.

FDA Panel Votes on Postpartum Depression Treatment Zulresso

By November 06, 2018

If approved, Zulresso would be the first drug approve for the treatment of postpartum depression.

FDA Committees Vote on Opioid System Modulator for MDD Treatment

By November 05, 2018

In the meeting documents, the panel presented a scenario which illustrated their concerns regarding potentially complex drug interactions that may occur in the population for which the drug is intended.

More Children Visiting Pediatric EDs for Mental Health

November 02, 2018

Over time, there was an increase in the rates of mental health visits, from 50.4 to 78.5 per 100,000 children in 2012 and 2016, respectively.

New Blood Test Identifies Metabolic Subtypes Linked to Autism Spectrum Disorder

By November 02, 2018

The NPDX AA test works by detecting amine imbalances in a child's fasting blood sample with very precise thresholds that were identified and validated based on samples from the Children's Autism Metabolome Project (CAMP) study (N=1100) in patients aged 18 to 48 months

Diagnoses, Treatment of Mental Health Conditions Up in College

October 31, 2018

The highest odds ratios were seen for anxiety, panic attacks, and attention deficit hyperactivity disorder (odds ratios, 1.68, 1.61, and 1.4, respectively).

Neither Haloperidol, Ziprasidone Shortens Delirium in ICU

October 26, 2018

The researchers found that patients were exposed to a trial drug or placebo for a median duration of four days. The median number of days alive without delirium or coma was 8.5, 7.9, and 8.7 in the placebo, haloperidol, and ziprasidone groups (P=0.26 for overall effect across trial groups).

Psilocybin Gets Breakthrough Tx Designation for Treatment-Resistant Depression

By October 24, 2018

The designation was granted to COMPASS Pathways, a life sciences company investigating psilocybin in a Phase 2b trial involving 216 patients at multiple sites across Europe and North America.

Vortioxetine Beats Escitalopram in Improving SSRI-Induced Sexual Dysfunction

By October 22, 2018

In the 8-week, randomized, double-blind study, patients with depression who had TESD (N=447) while taking an SSRI (eg, paroxetine, sertraline or citalopram) were switched to Trintellix or escitalopram, due to SSRI-induced sexual dysfunction.

Mortality Due to Suicide, Alcohol, Accidents Up in Diabetes

October 19, 2018

Among the 434,629 individuals included in the researcher, there were 2832 deaths due to alcohol, 3187 deaths due to accidents, and 853 deaths due to suicide during a mean follow-up of 7.1 years.

Dose Range of IV Ketamine for Adjunct Tx of Depression Tested

October 17, 2018

Compared with the active placebo, the infusions of ketamine were relatively well tolerated, except for greater dissociative symptoms and transient blood pressure elevations with the higher doses.

Sexual Harassment, Assault Tied to Women's Health Issues

October 05, 2018

Among women not taking antihypertensives, sexual harassment was correlated with significantly increased odds of stage 1 or 2 hypertension (odds ratio, 2.36) as well as clinically poor sleep (odds ratio, 1.89) after adjustment for covariates.

Abuse of Antidepressant for Weight Loss Leads to Seizures in Patient With Bulimia Nervosa

By October 03, 2018

The patient obtained prescriptions for bupropion XR from psychiatrists and primary care physicians who were not aware of her past medical history.

High HbA1c After T1DM Diagnosis Predicts Psychiatric Comorbidity

October 03, 2018

Higher risk for psychiatric diagnoses was predicted by high average HbA1c levels during the first 2 years of diabetes onset.

Global Cognition Up for Youth Meeting Movement Guidelines

October 02, 2018

The researchers found that the mean number of guidelines met was 1.1; 51, 37, and 18% of participants met the daily recommendations for sleep time (9 to 11 hours/night), screen time (2 hours or less), and physical activity (60 minutes or more), respectively.

NDA Submitted for Novel Schizophrenia Treatment Lumateperone

By September 28, 2018

Lumateperone, a first-in-class molecule, works via potent interactions at 5-HT2A receptors, serotonin transporters, and D1 receptors with indirect glutamatergic modulation.

Researchers Recommend Reclassification of Psilocybin

By September 27, 2018

Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I agent as it has not been approved by the Food and Drug Administration (FDA) for any therapeutic use.

FDA to Review Vraylar sNDA for Treatment of Bipolar Depression

By September 26, 2018

The sNDA included findings from the RGH-MD-53, RGH-MD-54, and RGH-MD-56 trials in which cariprazine was associated with greater improvement in change from baseline to week 6 on the Montgomery Asberg Depression Rating scale (MADRS) total score vs placebo in bipolar I patients.

Psychiatric Adverse Effects of Disease-Modifying Therapies Assessed in MS Patients

By September 25, 2018

The primary outcome measure of the study was the frequency of any adverse psychiatric effect observed during treatment with one of these agents.